Cargando…
Cortical thickness in relation to clinical symptom onset in preclinical AD
Mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia are preceded by a phase of disease, referred to as ‘preclinical AD’, during which cognitively normal individuals have evidence of AD pathology in the absence of clinical impairment. This study examined whether a magnetic reso...
Autores principales: | Pettigrew, Corinne, Soldan, Anja, Zhu, Yuxin, Wang, Mei-Cheng, Moghekar, Abhay, Brown, Timothy, Miller, Michael, Albert, Marilyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932610/ https://www.ncbi.nlm.nih.gov/pubmed/27408796 http://dx.doi.org/10.1016/j.nicl.2016.06.010 |
Ejemplares similares
-
Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease
por: Pettigrew, Corinne, et al.
Publicado: (2017) -
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
por: Younes, Laurent, et al.
Publicado: (2019) -
Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD
por: Gross, Alden L., et al.
Publicado: (2019) -
Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood
por: Pettigrew, Corinne, et al.
Publicado: (2022) -
Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)